AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18422741 — intervention group
Group type: EXPERIMENTAL
Intervention: Women without flushing after drinking
Number of subjects: 1616
Study 16948934 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiripentol (n = 17)
Number of subjects: 67
Study 16948934 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 67
Study 12930169 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine L-tartrate (2 g per day)
Number of subjects: 10
Study 12930169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11139109 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (2 x 10^6 KIU pre-CPB, 2 x 10^6 KIU in prime, 500,000 KIU/hr during CPB)
Number of subjects: 20
Study 11139109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9110123 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG-CoA reductase inhibitors (fluvastatin, lovastatin, pravastatin, simvastatin)
Number of subjects: 0
Study 9110123 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrates (bezafibrate, fenofibrate, gemfibrozil)
Number of subjects: 0
Study 9110123 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day
Number of subjects: 0
Study 9110123 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 17.3 mg/day or 20 mg/day
Number of subjects: 0
Study 9110123 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate
Number of subjects: 0
Study 1283370 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 1283370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3828570 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 6
Study 3828570 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 6
Study 3828570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30178240 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal
Number of subjects: 42
Study 30178240 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 30482480 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly
Number of subjects: 0
Study 30482480 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone palmitate once-monthly
Number of subjects: 0
Study 27529625 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (10 weeks)
Number of subjects: 25
Study 25384814 — intervention group
Group type: EXPERIMENTAL
Intervention: My Own Health Report (MOHR) assessment completed by staff
Number of subjects: 3591
Study 25384814 — intervention group
Group type: EXPERIMENTAL
Intervention: My Own Health Report (MOHR) assessment completed by patients
Number of subjects: 3591
Study 25384814 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of MOHR
Number of subjects: 3591
Study 25384814 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adoption of MOHR by practices
Number of subjects: 3591
Study 25384814 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustainability of MOHR assessment
Number of subjects: 3591
Study 23165413 — intervention group
Group type: EXPERIMENTAL
Intervention: Online application of SCIP-S
Number of subjects: 30
Study 23165413 — intervention group
Group type: COMPARATOR
Intervention: Traditional application of SCIP-S
Number of subjects: 30
Study 20198649 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 32
Study 20198649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17650131 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal training in elaborative reminiscing
Number of subjects: 115
Study 15162916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardixin (0.25 mg)
Number of subjects: 12
Study 15162916 — intervention group
Group type: COMPARATOR
Intervention: Lanoxin (0.25 mg)
Number of subjects: 12
Study 11641292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pet ownership with lisinopril (20 mg/d)
Number of subjects: 48
Study 11641292 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (20 mg/d) only
Number of subjects: 48
Study 9842768 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragile-X syndrome group
Number of subjects: 0
Study 9842768 — intervention group
Group type: COMPARATOR
Intervention: Control groups (mainstream schoolchildren)
Number of subjects: 0
Study 7978396 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming (Group I)
Number of subjects: 22
Study 7978396 — intervention group
Group type: COMPARATOR
Intervention: Passive cooling (Group II)
Number of subjects: 22
Study 2692407 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐day treatment of daily 2‐h infusions of 0.5 mg/kg in 250 ml of saline (group A)
Number of subjects: 33
Study 2692407 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 24‐h infusions of 1.5 mg/kg (group B)
Number of subjects: 33
Study 2692407 — intervention group
Group type: COMPARATOR
Intervention: Single 24‐h infusions of 0.5 mg/kg in 1 liter of saline (group C)
Number of subjects: 33
Study 2692407 — intervention group
Group type: COMPARATOR
Intervention: Group C (0.5 mg/kg in 1 liter of saline)
Number of subjects: 33
Study 2692407 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 33
Study 30454019 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible family visitation model (FFVM) - 12 consecutive ICU visiting hours per day
Number of subjects: 100
Study 30454019 — intervention group
Group type: COMPARATOR
Intervention: Restrictive family visitation model (RFVM) - < 4.5 ICU visiting hours per day
Number of subjects: 100
Study 28939582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention messages delivered via mobile app
Number of subjects: 570
Study 28939582 — intervention group
Group type: COMPARATOR
Intervention: Control messages about trial participation
Number of subjects: 570
Study 25448244 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented motor learning intervention
Number of subjects: 40
Study 25448244 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise program
Number of subjects: 40
Study 22784703 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay Cool Kids intervention
Number of subjects: 264
Study 22784703 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 264
Study 22027717 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloon (SeQuent Please, B-Braun)
Number of subjects: 0
Study 22027717 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (Xience V/Xience Prime, Abbott Vascular)
Number of subjects: 0
Study 18438223 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex training program (2 sessions per week for 10 weeks)
Number of subjects: 25
Study 18438223 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; n = 10)
Number of subjects: 25
Study 16536810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy with liquid nitrogen
Number of subjects: 89
Study 16536810 — intervention group
Group type: COMPARATOR
Intervention: Curettage and electrodesiccation
Number of subjects: 89
Study 15055043 — intervention group
Group type: EXPERIMENTAL
Intervention: Loco-Regional Anaesthesia (LRA)
Number of subjects: 72
Study 15055043 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 72
Study 16192522 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine 2 mg
Number of subjects: 215
Study 16192522 — intervention group
Group type: COMPARATOR
Intervention: placebo (control)
Number of subjects: 215
Study 10492856 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined continuation ECT and flupenthixol
Number of subjects: 51
Study 10492856 — intervention group
Group type: COMPARATOR
Intervention: Continuation ECT alone
Number of subjects: 51
Study 10492856 — intervention group
Group type: COMPARATOR
Intervention: Flupenthixol alone
Number of subjects: 51
Study 10492856 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance ECT combined with neuroleptic medication (Phase III study)
Number of subjects: 51
Study 8567331 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hyperfractional radiotherapy with bronchial arterial infusion of anticancer drugs (Group 1, 30 cases)
Number of subjects: 126
Study 8567331 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of conventional radiotherapy with bronchial arterial infusion of anticancer drugs (Group 2, 33 cases)
Number of subjects: 126
Study 8567331 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of systemic chemotherapy and split-course radiotherapy (Group 3, 33 cases)
Number of subjects: 126
Study 8567331 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy only (Group 4, 30 cases)
Number of subjects: 126
Study 1843989 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of chloral hydrate (CH) and hydroxyzine
Number of subjects: 15
Study 1843989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1843989 — intervention group
Group type: COMPARATOR
Intervention: Oral examination
Number of subjects: 15
Study 7043008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg four times daily for seven days)
Number of subjects: 6
Study 7043008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 28291891 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation followed by monitored home-based program
Number of subjects: 165
Study 28291891 — intervention group
Group type: COMPARATOR
Intervention: Home-based rehabilitation alone
Number of subjects: 165
Study 28291891 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation
Number of subjects: 165
Study 28291891 — intervention group
Group type: COMPARATOR
Intervention: Home-based rehabilitation
Number of subjects: 165
Study 24628110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive arousal (trauma video)
Number of subjects: 34
Study 24628110 — intervention group
Group type: COMPARATOR
Intervention: Control (pleasant video)
Number of subjects: 34
Study 24491072 — intervention group
Group type: EXPERIMENTAL
Intervention: SB in-person BASICS
Number of subjects: 783
Study 24491072 — intervention group
Group type: COMPARATOR
Intervention: SB web BASICS (with and without friends)
Number of subjects: 783
Study 24491072 — intervention group
Group type: COMPARATOR
Intervention: General BASICS
Number of subjects: 783
Study 24491072 — intervention group
Group type: EXPERIMENTAL
Intervention: SB in-person BASICS with friend
Number of subjects: 783
Study 24491072 — intervention group
Group type: COMPARATOR
Intervention: SB web BASICS with friend
Number of subjects: 783
Study 24491072 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 783
Study 23534280 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterosorbent White Coal (aerosil)
Number of subjects: 0
Study 19059524 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified transdermal HRT (micronized 17beta-estradiol and progesterone)
Number of subjects: 75
Study 19059524 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally given HST (Cyclo-Menorette)
Number of subjects: 75
Study 19059524 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 75
Study 17302660 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D
Number of subjects: 124
Study 17302660 — intervention group
Group type: COMPARATOR
Intervention: 200 IU vitamin D
Number of subjects: 124
Study 17302660 — intervention group
Group type: COMPARATOR
Intervention: 400 IU vitamin D
Number of subjects: 124
Study 17302660 — intervention group
Group type: COMPARATOR
Intervention: 600 IU vitamin D
Number of subjects: 124
Study 17302660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 15371986 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (hepatic/intestinal CYP3A induction)
Number of subjects: 0
Study 15371986 — intervention group
Group type: EXPERIMENTAL
Intervention: Troleandomycin (hepatic/intestinal CYP3A inhibition)
Number of subjects: 0
Study 15371986 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (selective intestinal CYP3A inhibition)
Number of subjects: 0
Study 15371986 — intervention group
Group type: COMPARATOR
Intervention: Nothing (control)
Number of subjects: 0
Study 11606958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal endoscopy
Number of subjects: 30
Study 11606958 — intervention group
Group type: COMPARATOR
Intervention: Lateral cephalometric radiography
Number of subjects: 30
Study 9682184 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural advice for the child's sleep problem
Number of subjects: 30
Study 9682184 — intervention group
Group type: COMPARATOR
Intervention: No behavioural advice (Control)
Number of subjects: 30
Study 7991070 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH, 500 micrograms)
Number of subjects: 28
Study 7991070 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-releasing hormone (GHRH, 100 micrograms)
Number of subjects: 28
Study 7991070 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (VIP, 100 micrograms)
Number of subjects: 28
Study 7991070 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide histidine methionine (PHM, 100 micrograms)
Number of subjects: 28
Study 2663151 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (AMI) 75 mg p.o.t.i.d. for 5 weeks
Number of subjects: 106
Study 2663151 — intervention group
Group type: COMPARATOR
Intervention: Mianserin (MIA) 60 mg p.o.t.i.d. for 5 weeks
Number of subjects: 106
Study 2663151 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (TRA) 150 mg p.o.t.i.d. for 5 weeks
Number of subjects: 106
Study 30048227 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy (n = 12)
Number of subjects: 24
Study 30048227 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control group, n = 12)
Number of subjects: 24
Study 30081694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional CO2 laser followed by topical compound betamethasone solution plus NB‐UVB (5 sessions, one month apart)
Number of subjects: 289
Study 30081694 — intervention group
Group type: COMPARATOR
Intervention: Topical betamethasone cream once a day plus NB‐UVB (3 times per week)
Number of subjects: 289
Study 28779371 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose (0.6 mg/day)
Number of subjects: 3000
Study 28779371 — intervention group
Group type: COMPARATOR
Intervention: No drugs (control)
Number of subjects: 3000
Study 26075646 — intervention group
Group type: EXPERIMENTAL
Intervention: Running absorbable suture placement at the staple line
Number of subjects: 146
Study 26075646 — intervention group
Group type: COMPARATOR
Intervention: No suture placement
Number of subjects: 146
Study 23258816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6492
Study 23258816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6492
Study 23258816 — intervention group
Group type: COMPARATOR
Intervention: Ranolazine vs Placebo
Number of subjects: 6492
Study 21329525 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-weeks exercise program with focus on fall prevention delivered by specifically trained local physiotherapists
Number of subjects: 382
Study 21329525 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 382
Study 20921349 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/STD risk-reduction intervention
Number of subjects: 1057
Study 20921349 — intervention group
Group type: COMPARATOR
Intervention: Health promotion control intervention
Number of subjects: 1057
Study 17400624 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in clinical trials
Number of subjects: 29
Study 17400624 — intervention group
Group type: COMPARATOR
Intervention: Declining participation in clinical trials
Number of subjects: 29
Study 17400624 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and feelings towards trials
Number of subjects: 29
Study 17400624 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in pharmaceutical industry and doctors
Number of subjects: 29
Study 17400624 — intervention group
Group type: EXPERIMENTAL
Intervention: Public control measures
Number of subjects: 29
Study 15752392 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block
Number of subjects: 48
Study 15752392 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1 microg kg(‐1) intravenous before skin incision)
Number of subjects: 48
Study 12034600 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mL of a nonionic contrast agent (250 mg I/mL) injected at a 3 mL/sec flow rate
Number of subjects: 200
Study 12034600 — intervention group
Group type: COMPARATOR
Intervention: 80 mL of the same contrast agent injected at a 4 mL/sec flow rate
Number of subjects: 200
Study 10438694 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial or clinical management (CM)
Number of subjects: 0
Study 10438694 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive CM
Number of subjects: 0
Study 7495046 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle training with individual choice of physical loading (group 2)
Number of subjects: 107
Study 7495046 — intervention group
Group type: COMPARATOR
Intervention: Bicycle training with preset intensity (50% of individual exercise tolerance) (group 1)
Number of subjects: 107
Study 2312777 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol CR/ZOK 200 mg
Number of subjects: 12
Study 2312777 — intervention group
Group type: COMPARATOR
Intervention: metoprolol Durules 200 mg
Number of subjects: 12
Study 2312777 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 7191754 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 10
Study 7191754 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparity
Number of subjects: 10
Study 30776899 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic inulin‐type fructans (6 g/day)
Number of subjects: 258
Study 30776899 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (maltodextrin)
Number of subjects: 258
Study 30776899 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic inulin‐type fructans during antibiotic treatment
Number of subjects: 258
Study 30776899 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 258
Study 30776899 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic supplementation
Number of subjects: 258
Study 28813425 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic education module
Number of subjects: 933
Study 28813425 — intervention group
Group type: COMPARATOR
Intervention: Static education module
Number of subjects: 933
Study 25530426 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (varenicline + bupropion SR)
Number of subjects: 505
Study 23657861 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 40
Study 23657861 — intervention group
Group type: COMPARATOR
Intervention: Titanium tack
Number of subjects: 40
Study 21948500 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) during HBOT
Number of subjects: 6
Study 21948500 — intervention group
Group type: COMPARATOR
Intervention: HBOT without NPWT
Number of subjects: 6
Study 19807887 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml x kg(‐1) of 1% lidocaine with epinephrine 0.5 microg x kg(‐1)
Number of subjects: 68
Study 19807887 — intervention group
Group type: COMPARATOR
Intervention: Normal saline intravenously
Number of subjects: 68
Study 16780671 — intervention group
Group type: EXPERIMENTAL
Intervention: Akatinol memantine 5 mg/d in first week, 10 mg/d in second week, 15 mg/d in third week and 20 mg/d from fourth to sixteenth week
Number of subjects: 100
Study 16780671 — intervention group
Group type: COMPARATOR
Intervention: Donepezil 5 mg/d
Number of subjects: 100
Study 15146342 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 142
Study 15146342 — intervention group
Group type: COMPARATOR
Intervention: low-dose haloperidol
Number of subjects: 142
Study 12146184 — intervention group
Group type: EXPERIMENTAL
Intervention: VACUTEX capillary action wound dressing
Number of subjects: 35
Study 12146184 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol for the treatment of sloughy and necrotic wounds
Number of subjects: 35
Study 8985633 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin 0.1% solution
Number of subjects: 51
Study 8985633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 8260856 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine pamoate (10(‐5) M in 2 ml)
Number of subjects: 156
Study 8260856 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (25 mg in 2 ml)
Number of subjects: 156
Study 8260856 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2 ml)
Number of subjects: 156
Study 2888651 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (1/3, 2/3, and full maximum tolerable dose)
Number of subjects: 6
Study 2888651 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (10 mg to males, 8 mg to females)
Number of subjects: 6
Study 2888651 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (1 mg)
Number of subjects: 6
Study 2888651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31539289 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoinjector (AI)
Number of subjects: 180
Study 31539289 — intervention group
Group type: COMPARATOR
Intervention: Accessorized prefilled syringe (APFS)
Number of subjects: 180
Study 31539289 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh administration
Number of subjects: 180
Study 31539289 — intervention group
Group type: COMPARATOR
Intervention: APFS vs. AI
Number of subjects: 180
Study 31539289 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices (AI and APFS)
Number of subjects: 180
Study 30418198 — intervention group
Group type: EXPERIMENTAL
Intervention: Copenhagen adduction (CA)
Number of subjects: 42
Study 30418198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding hip (SH)
Number of subjects: 42
Study 30418198 — intervention group
Group type: COMPARATOR
Intervention: Matched control (C)
Number of subjects: 42
Study 28875250 — intervention group
Group type: EXPERIMENTAL
Intervention: Iris registration FEMTOLASIK
Number of subjects: 59